SCHEMBL2970766

SCHEMBL2970766

CC(C)N1CCC(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGDS O60760 1/20 0.49
FAAH O00519 1/20 0.47
SCN9A Q15858 4/20 0.43
MAPT P10636 3/20 0.43
AR P10275 2/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
OGA O60502 1/20 0.41
GAA P10253 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2983037 0.88 SMN1; SMN2 (0.44) L3MBTL1SMN1; SMN2ALDH1A1FAAHAR
SCHEMBL2981922 0.87 ALDH1A1 (0.54) L3MBTL1SMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL24213037 0.86 L3MBTL1 (0.51) L3MBTL1SMN1; SMN2ALDH1A1HPGDSFAAH
SCHEMBL2979822 0.85 ALDH1A1 (0.53) L3MBTL1SMN1; SMN2ALDH1A1HPGDSFAAH
SCHEMBL2986385 0.85 RAB9A (0.58) L3MBTL1SMN1; SMN2ALDH1A1FAAHMAPT
SCHEMBL2970555 0.84 ALDH1A1 (0.43) L3MBTL1SMN1; SMN2ALDH1A1HPGDSAR
SCHEMBL2977247 0.84 GAA (0.49) SMN1; SMN2ALDH1A1FAAHMAPTRAB9A
SCHEMBL2970736 0.84 LTA4H (0.41) L3MBTL1SMN1; SMN2ALDH1A1FAAHRAB9A
SCHEMBL2978210 0.84 MAOA (0.42) L3MBTL1SMN1; SMN2ALDH1A1ARTP53
SCHEMBL2979648 0.83 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1MAPTTP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945635-B1 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-05-06 EP claimed
CN-101243078-A Thiazolyl piperidine derivatives useful as h3 receptor modulators HOFFMANN LA ROCHE (CH) 2008-08-13 CN claimed
EP-1945635-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-23 EP claimed
US-20070043083-A1 Thiazolyl piperidine derivatives HOFFMANN-LA ROCHE INC. 2007-02-22 US claimed
WO-2007020213-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO claimed
US-7786143-B2 Thiazolyl piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2010-08-31 US disclosed
EP-1945635-B1 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-05-06 EP disclosed
CN-101243078-A Thiazolyl piperidine derivatives useful as h3 receptor modulators HOFFMANN LA ROCHE (CH) 2008-08-13 CN disclosed
EP-1945635-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-23 EP disclosed
US-20070043083-A1 Thiazolyl piperidine derivatives HOFFMANN-LA ROCHE INC. 2007-02-22 US disclosed
WO-2007020213-A2 THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043083-A1 Thiazolyl piperidine derivatives HRH3, HRH4, H1-3 L3MBTL1 3337/4885SMN1; SMN2 3880/4885ALDH1A1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.